1. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. (22nd December 2016) Authors: Moore, M.; Gill, S.; Asmis, T.; Berry, S.; Burkes, R.; Zbuk, K.; Alcindor, T.; Jeyakumar, A.; Chan, T.; Rao, S.; Spratlin, J.; Tang, P. A.; Rothenstein, J.; Chan, E.; Bendell, J.; Kudrik, F.; Kauh, J.; Tang, S.; Gao, L.; Kambhampati, S. R. P. Journal: Annals of oncology Issue: Volume 27:Number 12(2016:Dec.) Page Start: 2216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗